J. A. Dudakov, A. M. Hanash, and M. R. Van-den-brink, Interleukin-22: immunobiology and pathology, Annu Rev Immunol, vol.33, pp.747-785, 2015.

, The Authors, Ltd on behalf of Australian and New Zealand Society for Immunology, 2020.

C. L. Zindl, J. F. Lai, and Y. K. Lee, IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis, Proc Natl Acad Sci, vol.110, pp.12768-12773, 2013.

M. J. Xu, D. Feng, and H. Wang, IL-22 ameliorates renal ischemia-reperfusion injury by targeting proximal tubule epithelium, J Am Socf Nephrol, vol.25, pp.967-977, 2014.

Y. Zheng, P. A. Valdez, and D. M. Danilenko, Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens, Nat Med, vol.14, pp.282-289, 2008.

G. F. Sonnenberg, L. A. Monticelli, and T. Alenghat, Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria, Science, vol.336, pp.1321-1325, 2012.

M. Weidenbusch, S. Rodler, and H. J. Anders, Interleukin-22 in kidney injury and regeneration, Am J Physiol Renal Physiol, vol.308, pp.1041-1046, 2015.

M. Weidenbusch, S. Song, and T. Iwakura, IL-22 sustains epithelial integrity in progressive kidney remodeling and fibrosis, Physiol Rep, vol.6, p.13817, 2018.

O. P. Kulkarni, I. Hartter, and S. R. Mulay, Toll-like receptor 4-induced IL-22 accelerates kidney regeneration, J Am Soc Nephrol, vol.25, pp.978-989, 2014.

A. C. Gnirck, M. Wunderlich, and M. Becker, Endogenous IL-22 is dispensable for experimental glomerulonephritis, Am J Physiol Renal Physiol, vol.316, pp.712-722, 2019.

M. W. Plank, G. E. Kaiko, and S. Maltby, Th22 cells form a distinct Th Lineage from Th17 cells in vitro with unique transcriptional properties and Tbet-dependent Th1 plasticity, J Immunol, vol.198, pp.2182-2190, 2017.

G. Cameron, K. M. Cautivo, and S. Loering, Group 2 innate lymphoid cells are redundant in experimental renal ischemia-reperfusion injury, Front Immunol, vol.10, p.826, 2019.

E. Guttman-yassky, P. M. Brunner, and A. U. Neumann, Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-tosevere atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial, J Am Acad Dermatol, vol.78, pp.872-881, 2018.

K. Y. Tang, J. Lickliter, and Z. H. Huang, Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects, Cell Mol Immunol, vol.16, pp.473-482, 2018.